Hepatoprotective effect of Arazyme on CCl4-induced acute hepatic injury in SMP30 knock-out mice

Park, Jin‐Kyu; Jeong, Da‐Hee; Park, Ho-Yong; Son, Kwang‐Hee; Shin, Dong‐Ha; Do, Sun-Hee; Yang, Hea-Eun; Yuan, Dong‐Wei; Hong, Il-Hwa; Goo, Moon-Jung; Lee, Hye-Rim; Ki, Mi-Ran; Ishigami, Akihito; Jeong, Kyu‐Shik

doi:10.1016/j.tox.2008.01.006

Cited by 32 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although arazyme has a protective effect against hepatic injury, other protective and therapeutic functions, including inflammation, have not yet been reported (3). Previous studies have identified novel inhibitory materials against the inflammatory response in endothelial cells such as Ecklonia cava extracts and cilostazol (9,11).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of arazyme on the lipopolysaccharide-induced inflammatory response in human endothelial cells

Kim

Yang

Shin

et al. 2014

Molecular Medicine Reports

Self Cite

View full text Add to dashboard Cite

Abstract. Arazyme is a novel extracellular metalloprotease secreted by Aranicola proteolyticus. Endothelial cells are involved in the pathogenesis of a number of inflammatory diseases, induce uncontrolled cell viability and express various inflammatory mediators, including cytokines, chemokines, adhesion molecules and reactive oxygen species (ROS). In the current study, human umbilical vein endothelilal cells (HUVECs) were used to investigate the anti-inflammatory effects of arazyme following lipopolysaccharide (LPS) stimulation. Apoptosis of HUVECs due to LPS was inhibited by arazyme. In various inflammatory responses induced by LPS, arazyme inhibited the secretion of the monocyte chemoattractant protein-1 and interleukin-6, and the expression of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1. Arazyme also suppressed ROS production in HUVECs. The action of arazyme was not associated with NF-κB activity in HUVECs. These results indicate that arazyme has anti-inflammatory properties in inflamed endothelial cells and may be useful as a therapeutic agent for inflammatory diseases associated with endothelial cells.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A previous report demonstrated that arazyme has hepatoprotective activity against carbon tetrachloride-induced hepatic injury and that the mechanism involves increased expression of SMP30 and antioxidant proteins (3).…”

Section: Introductionmentioning

confidence: 98%

Effect of arazyme on the lipopolysaccharide-induced inflammatory response in human endothelial cells

Kim

Yang

Shin

et al. 2014

Molecular Medicine Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…Arazyme is a metalloprotease and its effect on the pathogenesis of allergic inflammation is unclear, however, it is known to protect hepatocytes that have been injured by CCl4 (14). The efficacy of arazyme as an inhibitor of inflammation was determined by evaluating the alteration of cytokines in inflammatory cells and skin barrier proteins in keratinocytes.…”

Section: Discussionmentioning

confidence: 99%

“…Arazyme protects against acute hepatic injury by enhancing SMP30 expression, which suppresses the transforming growth factor-β (TGF-β)/Smad pathway and by increasing the expression of anti-oxidant proteins (14).…”

Section: Introductionmentioning

confidence: 99%

Arazyme inhibits cytokine expression and upregulates skin barrier protein expression

Kim

Shin³

et al. 2013

Molecular Medicine Reports

Self Cite

View full text Add to dashboard Cite

Abstract. In the present study, the inhibitory effect of arazyme on allergic inflammation was investigated by evaluating the alteration of cytokine production and expression of skin barrier proteins in immune and HaCaT human keratinocyte cells. THP-1 human monocytic and EoL-1 human eosinophilic cells were treated with Dermatophagoides pteronissinus extract (DpE). Monocyte chemotactic protein-1 (MCP-1)/CCL2, interleukin (IL)-6 and IL-8 increased following DpE treatment and arazyme significantly blocked the increase of MCP-1, IL-6 and IL-8 expression in cell types. Secretion of MCP-1, IL-6 and IL-8 induced by lipopolysaccharide in THP-1 cells was also inhibited by arazyme treatment. Arazyme inhibited the secretion of IL-6 and IL-8 due to phorbol 12-myristate 13-acetate and calcium ionophores in human mast cells. Arazyme blocked the secretion of thymus and activation-regulated chemokine (TARC)/CCL17, MCP-1, IL-6 and IL-8 due to tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in HaCaT cells. TNF-α and IFN-γ suppressed the expression of skin barrier proteins, including filaggrin, involucrin and loricrin. By contrast, arazyme increased the expression of filaggrin, involucrin and loricrin. These results may contribute to the development of a therapeutic drug for the treatment of allergic diseases, including atopic dermatitis.

show abstract

“…It has also been reported that when SMP30 decreases, resistance to infectious pathogens would decrease along with organ function, resulting in aging of the organs [9][10][11] .…”

Section: Introductionmentioning

confidence: 99%

Lack of Grafted Liver Rejuvenation in Adult-to-Pediatric Liver Transplantation

et al. 2010

View full text Add to dashboard Cite

show abstract

Hepatoprotective effect of Arazyme on CCl4-induced acute hepatic injury in SMP30 knock-out mice

Cited by 32 publications

References 26 publications

Effect of arazyme on the lipopolysaccharide-induced inflammatory response in human endothelial cells

Effect of arazyme on the lipopolysaccharide-induced inflammatory response in human endothelial cells

Arazyme inhibits cytokine expression and upregulates skin barrier protein expression

Lack of Grafted Liver Rejuvenation in Adult-to-Pediatric Liver Transplantation

Contact Info

Product

Resources

About